[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334682-105":59,"doc-detail-334682-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pias-family-in-cancer-from-basic-mechanisms-to-clinical-applications","PIAS family in cancer: from basic mechanisms to clinical applications","","Protein inhibitors of activated STATs (PIAS) are cytokine signaling proteins that activate activator-mediated gene transcription and act as versatile regulators of multiple cellular proteins. Dysregulated PIAS activity links to aberrant oncogenic gene expression across diverse cancers, with PIAS1 and PIAS3 most frequently implicated. The review details PIAS/SUMO roles in controlling transcription factors, highlights antagonistic functions by cancer type, emphasizes PIAS proteins as therapeutic targets for STAT pathway inhibition, and summarizes natural activators with potential anticancer effects.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pias-family-in-cancer-from-basic-mechanisms-to-clinical-applications/334682/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pias-family-in-cancer-from-basic-mechanisms-to-clinical-applications/334682.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are PIAS proteins and what role do they play in cytokine signaling?","Question",{"text":113,"@type":114},"PIAS proteins are protein inhibitors of activated STAT that regulate cytokine signaling by activating activator-mediated gene transcription. They function as cellular regulators and modulate STAT-related transcriptional control.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which PIAS family members are most frequently associated with cancer development?",{"text":118,"@type":114},"PIAS1 and PIAS3 are the most frequently reported PIAS family members in cancer development. Their expression is often modulated in cancer cells.",{"name":120,"@type":111,"acceptedAnswer":121},"How does SUMOylation relate to PIAS function in tumors?",{"text":122,"@type":114},"PIAS proteins act as SUMO E3 ligase factors that promote SUMOylation of transcription factors, influencing cancer cell survival, proliferation, and differentiation. Attenuated PIAS-mediated SUMOylation contributes to tumorigenesis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},334682,1790111822,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 25 March 2024  \nDOI 10.3389/fonc.2024.1376633  \nOPEN ACCESS  \nEDITED BY  \nAlessandra di Masi, Roma Tre University, Italy  \nREVIEWED BY Yitao Qi,  \nShaanxi Normal University, China Shangze Li,  \nChongqing University, China  \n*CORRESPONDENCE Xiaomeng Li  \n [2022990077@gzhmu.edu.cn](2022990077@gzhmu.edu.cn)  \nRECEIVED 25 January 2024  \nACCEPTED 06 March 2024  \nPUBLISHED 25 March 2024  \nCITATION  \nLi X, Rasul A, Sharif Fand Hassan M (2024) PIAS family in cancer: from basic  \nmechanisms to clinical applications.  \nFront. Oncol. 14:1376633 .  \ndoi: 10.3389/fonc.2024.1376633  \nCOPYRIGHT  \n© 2024 Li, Rasul, Sharif and Hassan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPIAS family in cancer: from basic mechanisms to clinical applications  \nXiaomeng Li 1*, Azhar Rasul 2, Farzana Sharif 2 and Mudassir Hassan 2  \n1 KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong, China, 2 Department of Zoology, Government College University Faisalabad, Faisalabad, Pakistan  \nProtein inhibitors of activated STATs (PIAS) are proteins for cytokine signaling that activate activator-mediated gene transcription. These proteins, as versatile cellular regulators, have been described as regulators of approximately 60 proteins. Dysregulation of PIAS is associated with inappropriate gene expression that promotes oncogenic signaling in multiple cancers. Multiple lines of evidence have revealed that PIAS family members show modulated expressions in cancer cells. Most frequently reported PIAS family members in cancer development are PIAS1 and PIAS3 . SUMOylation as post-translational modiﬁer regulates several cellular machineries. PIAS proteins as SUMO E3 ligase factor promotes SUMOylation of transcription factors tangled cancer cells for survival, proliferation, and differentiation . Attenuated PIAS-mediated SUMOylation mechanism is involved in tumorigenesis. This review article provides the PIAS/SUMO role in the modulation of transcriptional factor control, provides brief update on their antagonistic function in different cancer types with particular focus on PIAS proteins as a bonaﬁde therapeutic target to inhibit STAT pathway in cancers, and summarizes natural activators that may have the ability to cure cancer.  \nKEYWORDS  \nPIAS, SUMOylation, transcriptional factor, signal transducers, activators of transcription factor (STAT)  \n1 The PIAS proteins  \nThe term PIAS (protein inhibitors of activated STAT) originates due to its cellular function, as all members of this family negatively regulates the STAT (1, 2) . The PIAS were primarily identiﬁed via yeast two hybrid (Y2H) technique. The PIAS proteins that are found in eukaryotes are evolutionary conserved from yeast and process versatile cellular regulatory function of approximately 60 proteins (3, 4) . The PIAS family comprises four genes, generating a total of seven proteins: PIAS1, PIASxa, PIASxb, PIAS3, PIAS3L, PIASy, and PIASyE6 (as called PIAS4) are reported in all eukaryotic and mammalian cells  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \n19526197. In eukaryotes, PIAS proteins play a key role in activating a wide range of cellular pathways, including nuclear transport through intracellular channels, Sma- and Mad-related proteins, along with DNA damage repair through the recruitment of transcription factors (5) .  \n2 Historical perspective  \nPIAS3 was ﬁrst identiﬁed in 1997 as an inhibitor of interferon alpha (IFN-a)-induced STAT3-mediated transcriptional regulation in cytoplasmic and nuclear extracts of human and mouse cell ","cbCaie5i6Zj3B1Ch","https://ap.wps.com/l/cbCaie5i6Zj3B1Ch","pdf",1947577,12,"English","# PIAS family in cancer: from basic mechanisms to clinical applications\n## The PIAS proteins\n## Historical perspective","[{\"question\":\"What are PIAS proteins and what role do they play in cytokine signaling?\",\"answer\":\"PIAS proteins are protein inhibitors of activated STAT that regulate cytokine signaling by activating activator-mediated gene transcription. They function as cellular regulators and modulate STAT-related transcriptional control.\"},{\"question\":\"Which PIAS family members are most frequently associated with cancer development?\",\"answer\":\"PIAS1 and PIAS3 are the most frequently reported PIAS family members in cancer development. Their expression is often modulated in cancer cells.\"},{\"question\":\"How does SUMOylation relate to PIAS function in tumors?\",\"answer\":\"PIAS proteins act as SUMO E3 ligase factors that promote SUMOylation of transcription factors, influencing cancer cell survival, proliferation, and differentiation. Attenuated PIAS-mediated SUMOylation contributes to tumorigenesis.\"}]","PIAS family in cancer: from basic mechanisms to clinical applications | PDF",1790007840]